close

Fundraisings and IPOs

Date: 2017-02-08

Type of information: Private placement

Company: Galena Biopharma (USA - OR)

Investors:

Amount:

Funding type: private placement

Planned used:

Others:

* On February 8, 2017, Galena Biopharma announced the pricing of an underwritten public offering of units with anticipated gross proceeds of $17,000,000 , before deducting underwriting discounts and commissions and estimated offering expenses payable by Galena. Each unit consists of one full share of its common stock and a warrant to purchase one share of its common stock and is priced at $1.00 per unit. The warrants are immediately exercisable at a price of $1.10 per share of common stock and will expire on the fifth anniversary of the date of issuance. The offering is expected to close on or about February 13, 2017 , subject to customary closing conditions.
Canaccord Genuity is acting as sole book-running manager for the offering.
* On February 7, 2017, Galena Biopharma announced it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock and warrants to purchase shares of its common stock. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Canaccord Genuity is acting as sole book-running manager for the offering.
The shares of common stock and warrants to purchase shares of common stock described above are being offered pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission ( SEC ). 

Therapeutic area:

Is general: Yes